Neurocrine Biosciences Inc (NBIX) is a publicly traded Healthcare sector company. As of July 15, 2026, NBIX trades at $170.24 with a market cap of $17.81B and a P/E ratio of 25.92. NBIX moved -1.38% today. Year to date, NBIX is +23.52%; over the trailing twelve months it is +30.45%. Its 52-week range spans $84.23 to $181.18. Analyst consensus is strong buy with an average price target of $199.11. Rallies surfaces NBIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for NBIX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $170.24 |
| Market Cap | $17.81B |
| P/E Ratio | 25.92 |
| EPS | $6.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $181.18 |
| 52-Week Low | $84.23 |
| Volume | 121.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.10B |
| Net Income | $668.60M |
| Gross Margin | 98.17% |
22 analysts cover NBIX: 0 strong buy, 19 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $199.11.